Television station WWOR solicited addiction expert, Dr. Cidambi’s opinion on Probuphine, an implantable form of buprenorphine, recently approved by the FDA. Probuphine is recommended for maintenance treatment of dependence on opiates. It is to be used to address opiate cravings and opiate withdrawal.
Dr. Cidambi is a leader in addiction treatment and innovator of safe and effective ambulatory (outpatient) detoxification level of care for alcohol, benzodiazepines, opiates, and suboxone. Prior to founding the Center for Network Therapy, she completed her residency in Psychiatry at Maimonides Medical Center in Brooklyn and an Addiction Medicine Fellowship at NYU/Bellevue Hospital in New York. Due to the successful detoxification program, Dr. Cidambi was featured frequently by media outlets, including NPR, CBS, NY Times, and Wall Street Journal.